Presented for research literature review only Grieco P et al
PubMed research supports that insulin resistance is a core factor in various health issues beyond diabetes, including fatty liver, cognitive impairment, and cardiovascular disease (Springer)
In January 2025, Novo Nordisk reported that a high dose of its obesity drug Wegovy led to greater weight loss than the approved regimen in a Phase III trial
He paid about $2,100 upfront for a year of the medication (which included additional fees from the telehealth platform), and a three-month supply shipped to his door within a few days
Adjusting your approach based on early results If you experience strong appetite suppression and steady weight loss during the first month, your dose escalation can proceed on schedule
The improvement mirrors neurological and gastric adaptation: your brain's GLP-1 receptors develop more efficient signaling, and your stomach's smooth muscle tissue adjusts to chronic slowed emptying